• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly July 2008 Issue

CenterWatch Monthly July 2008 Issue

July 15, 2008
CenterWatch Staff

Maine Moves First with Clinical Trial Transparency Law

Maine law now requires sponsor companies to publicly disclose information about most clinical trials of FDA-approved prescription drugs that are sold in Maine. Sponsors must document protocol details in a clinical trials registry and report results for key trial endpoints. About 45 pharmaceutical companies have complied with Maine’s law, but those companies and others have voiced serious concerns about how Maine’s law relates to federal requirements. The federal trial results database will preempt the Maine law, but Maine regulators insist that won’t be fully in place until at least 2010. In the intervening years, sponsors will have to be aware of what transparency regulations Maine and dozens of others states are implementing.

Regulatory and Ethical Issues in Gene Therapy Research

Scientific advances, including gene therapy research, often push the envelope on issues such as informed consent, continuing oversight, reporting serious adverse events, conflict of interest and determining risk versus benefit. There have been a number of changes in the government’s regulatory oversight of gene therapy trials. The unexpected death of a participant in a gene therapy trial in 2007 resulted in renewed scrutiny of these protocols and the approval process that allows them to go forward. To further advance the possibilities of treating cancers and other diseases, subjects who agree to enroll in gene therapy trials must be protected from harm.

Impact on Clinical Research of European Legislation FP7 Project Underway

The Impact on Clinical Research of European Legislation (ICREL) project is funded by the European Commission’s Seventh Framework Programme (FP7) to measure and analyze the direct and indirect impact of the European Union Clinical Trial Directive 2001/20/EC and EU-related legislation on all categories of clinical research. The one-year ICREL project is being carried out by a consortium composed of the European Forum for Good Practice (EFGCP), European Clinical Research Infrastructure Network (ECRIN), European Organisation for Research and Treatment of Cancer (EORTC), Hospital Clinic I Provincial de Barcelona and the Ethics Committee of the University of Vienna.

Eye On: Ovarian Cancer

Most ovarian cancers are classified as ovarian epithelial carcinomas, which originate from cells on the ovarian surface, or malignant germ cell tumors that originate from egg cells. According to the National Cancer Institute, there are 21,650 estimated new cases of ovarian cancer in the United States in 2008, and 15,520 deaths, making it the fourth most common cause of female cancer death.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing